-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
Persuading doctors to prescribe Aduhelm, the company's rigorously vetted Alzheimer's treatment drug, is undoubtedly a difficult battle for Biogen
This is the case with the Neurology Center in Washington, D.
A slogan picture of the clinic posted on Twitter read: "Biogen sales representatives are not allowed to enter the clinic or contact staff, doctors or patients.
This warning is only the most recent cold reception that Aduhelm has received since it received FDA approval in June
Part of the reason for the investigation was that the company reportedly had a good relationship with regulators before Aduhelm approved it
According to a note on its website, considering the high price of Aduhelm-the average annual treatment cost per patient is $56,000-and the ambiguous clinical benefits, doctors at the Neurology Center have agreed to refuse to use it until the dispute is clarified.
And Biogen itself admitted that the launch of Aduhelm was much slower than the Cambridge, Massachusetts-based company expected
When asked about the clinic’s slogan, a Biogen spokesperson told foreign media that the company encourages any patients who have been refused treatment to contact the company for help, adding that they remain “committed to providing all suitable patients with Aduhelm
Note: The original text has been deleted
